Page 29 - Advanced Accelerator Applications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novartis Pharma AG: Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer

Novartis Pharma AG: Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesIsabella zinckSamir shahJulie masowThomas hungerbuehlerSloan simpsonSusanne schaffertFiona phillipsAmerican society of clinical oncologyNovartis institutes for biomedical researchAstex pharmaceuticalsEuropean hematology associationNovartis strategy financial communicationsNovartis oncology communicationsNovartis us external communicationsExchange commission

Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer

Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Investegate |Telix Pharmaceuticals Limited Announcements | Telix Pharmaceuticals Limited: Telix Pharmaceuticals Appoints Mr Richard Valeix as EMEA President

Telix Pharmaceuticals Appoints Mr. Richard Valeix as EMEA President MELBOURNE, Australia and HERSTAL, Belgium, May 02, 2021 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Mr. Richard Valeix has joined the Telix executive leadership team in the role of President, Europe, Middle East and Africa (EMEA). Richard joins Telix with approximately twenty years of pharmaceutical industry experience, including radiopharmaceuticals, gained in senior executive leadership roles across a broad range of therapeutic product areas. Prior to joining Telix, Richard worked at Advanced Accelerator Applications (AAA), a Novartis Company where he served for seven years in the roles of General Manager for France, Switzerland, Belgium, Netherlands and Luxembourg, and Global Head of Marketing and Sales. Earlier in his career, Richard held senior sales, marketing and strategy roles at Ipsen and Roche, where he gained extensive experience in European mark

Waals gewestUnited statesStewart holmstromRichard valeixChristian behrenbruchTelix pharmaceuticalsNovartis companyAustralian securities exchangeTelix pharmaceuticals appoints mrUniversity marseille franceAustralian therapeutic goods administrationEuropean unionCorporate communicationsTelix pharmaceuticals limitedBusiness school marseilleInternational marketing program

Telix Pharmaceuticals Limited: Telix Pharmaceuticals Appoints Mr Richard Valeix as EMEA President

Telix Pharmaceuticals Limited: Telix Pharmaceuticals Appoints Mr. Richard Valeix as EMEA President MELBOURNE, Australia and HERSTAL, Belgium, May 02, 2021 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Mr. Richard Valeix has joined the Telix executive leadership team in the role of President, Europe, Middle East and Africa (EMEA). Richard joins Telix with approximately twenty years of pharmaceutical industry experience, including radiopharmaceuticals, gained in senior executive leadership roles across a broad range of therapeutic product areas. Prior to joining Telix, Richard worked at Advanced Accelerator Applications (AAA), a Novartis Company where he served for seven years in the roles of General Manager for France, Switzerland, Belgium, Netherlands and Luxembourg, and Global Head of Marketing and Sales. Earlier in his career, Richard held senior sales, marketing and strategy roles at Ipsen and Roche, where he gained extensiv

Waals gewestStewart holmstromRichard valeixChristian behrenbruchTelix pharmaceuticalsNovartis companyAustralian therapeutic goods administrationUniversity marseille franceEuropean unionCorporate communicationsTelix pharmaceuticals limitedBusiness school marseilleInternational marketing programPharmaceuticals limitedMiddle eastAdvanced accelerator applications

Novartis, Artios Pharma Target Cancer in Up-to-$1 3B DDR Collaboration

Novartis, Artios Pharma Target Cancer in Up-to-$1.3B DDR Collaboration April 7, 2021 Share Artios Pharma CEO Niall Martin, PhD Novartis has agreed to identify and validate next-generation DNA Damage Response (DDR) targets for precision cancer treatments using Artios Pharma’s discovery platform, through a collaboration that could generate more than $1.3 billion for Artios. The companies plan to discover and validate targets that enhance Novartis’ Radioligand Therapies (RLTs) through a three-year research collaboration. Novartis will select up to three exclusive DDR targets, and receive worldwide rights on these targets for use with its RLTs, which are designed to deliver targeted radiation to a specific subset of cancer cells with minimal effect on surrounding healthy cells.

New yorkUnited statesArix bioscienceArtios pharmaNiall martinMerck kgaSv health investorsIp groupMerck kgaaBabraham research campus in cambridgeNovarti radioligand therapiesAdvanced accelerator applicationsAbbvie venturesAndera partnersLife science partnersPfizer ventures